Osteoporosis is a systemic metabolic disease in which the delicate balance between bone-building cells called osteoblasts and bone-resorbing cells called osteoclasts tips decisively toward loss. The result is porous, fragile bone that fractures under trivial loads, and the human toll is enormous: hip fractures alone are associated with significant mortality within the first year, and the disease affects hundreds of millions of people worldwide, with prevalence rising steeply as populations age. Current pharmacological options, including bisphosphonates, denosumab, and parathyroid hormone analogues, can slow bone loss or stimulate bone formation, but each comes with limitations ranging from gastrointestinal irritation to rare but serious adverse effects such as osteonecrosis of the jaw. This therapeutic gap has fueled intense interest in natural compounds that might modulate bone metabolism with fewer side effects, and quercetin has long been a tantalizing candidate in that search.

Quercetin belongs to the flavonol subclass of flavonoids, a family of polyphenolic compounds that plants synthesize in response to environmental stress. Chemically, its structure is built around a three-ringed backbone decorated with five hydroxyl groups, a configuration that makes it a remarkably potent scavenger of reactive oxygen species. That antioxidant capacity is central to why bone researchers became interested in it in the first place. Oxidative stress is now recognized as a key driver of osteoporosis, particularly in the context of estrogen deficiency: reactive oxygen species push bone marrow mesenchymal stem cells away from the osteogenic lineage and toward adipogenic differentiation, meaning the stem cells that should become bone-forming osteoblasts instead become fat cells. Oxidative stress also promotes osteoclastogenesis, tipping the remodeling cycle further toward resorption. By neutralizing these reactive species, quercetin theoretically attacks the disease at one of its root causes rather than merely masking its symptoms.

To test that theory rigorously, the Chinese team conducted a systematic search of the Embase, MEDLINE, and Web of Science databases covering the literature up to March 2025, identifying comparative preclinical studies in which quercetin was administered to animal models of osteoporosis and compared against appropriate controls. The methodological rigor of each included trial was assessed using the SYRCLE risk of bias tool, a instrument specifically designed for laboratory animal research that evaluates domains such as sequence generation, allocation concealment, blinding, and selective outcome reporting. Statistical pooling was performed with Review Manager 5.4 software, with effects expressed as standardized mean differences, a metric that allows outcomes measured on different scales across different laboratories to be combined into a single coherent estimate. This is the essential work of meta-analysis: transforming a scattered literature of small, sometimes conflicting experiments into a quantitative statement about whether an effect is real.

The pooled results were consistently favorable to quercetin. Across the included trials, the compound improved bone tissue morphology as assessed by micro-computed tomography, the gold-standard imaging technique for quantifying three-dimensional bone microarchitecture in rodents. Key structural parameters, including bone volume fraction, trabecular thickness, and trabecular separation, all moved in the direction of healthier bone: more bone tissue, thicker structural struts, and wider spacing between trabeculae reversed. The meta-analysis also found that quercetin enhanced serum bone metabolism markers, the biochemical signals that reflect the ongoing tug-of-war between bone formation and bone resorption, and it increased bone mechanical strength, the ultimate functional endpoint that determines whether a bone will withstand the loads of daily life. In practical terms, animals treated with quercetin had bones that were structurally better built and mechanically more resilient than their untreated counterparts.

Perhaps the most actionable finding concerns dosage. The authors report that a potentially effective dose range in animal models falls between 100 and 150 milligrams per kilogram per day. This kind of dose-response information is invaluable for translating preclinical work toward clinical testing, because it gives future researchers a rational starting point for designing human trials rather than guessing at pharmacologically active levels. It is worth noting, however, that such doses in rodents are far higher than what any human could obtain from diet alone; a person eating a quercetin-rich diet typically consumes tens of milligrams per day, and even concentrated supplements deliver a small fraction of the normalized doses used in these animal experiments. Bioavailability is another persistent challenge, since quercetin is poorly absorbed and extensively metabolized in its native form, which is why some formulation strategies pair it with carrier molecules or use metabolites such as quercetin glycosides.

The mechanistic story that emerges from the review is a three-pronged one. First, quercetin’s antioxidative activity directly counters the reactive oxygen species that sabotage bone remodeling, protecting osteoblast precursors and reducing osteoclast activity, which the authors tracked in part through markers such as tartrate-resistant acid phosphatase, a classic enzymatic signature of bone-resorbing cells. Second, the compound promotes the osteogenic differentiation of bone marrow mesenchymal stem cells, nudging these multipotent cells toward becoming functional bone-forming osteoblasts, a process influenced by regulatory molecules including long non-coding RNAs that fine-tune gene expression during lineage commitment. Third, and perhaps most intriguingly for readers following the exploding field of gut-bone axis research, quercetin modulates the intestinal microbiota, increasing short-chain fatty acid production. Short-chain fatty acids are microbial metabolites with well-documented anti-inflammatory and bone-protective effects, and their elevation suggests that quercetin may act partly as a preclinical agent, reshaping the gut ecosystem in ways that ultimately benefit the skeleton.

The ovariectomized rodent, in which the ovaries are surgically removed to mimic the estrogen withdrawal of menopause, remains the workhorse model of postmenopausal osteoporosis, and it featured prominently in the included studies. While this model has proven its worth over decades of bone biology research, it is not a perfect proxy for human disease, and the authors are careful to frame their conclusions as evidence of a potential preventive effect rather than a demonstrated therapy. The SYRCLE assessment, though not detailed in full in the abstract-level reporting, serves as a reminder that laboratory animal studies are vulnerable to biases that can inflate apparent effects, and that small sample sizes, in this case 325 animals across fifteen trials, leave room for statistical uncertainty around the pooled estimates. Heterogeneity across studies, arising from differences in species, dose, route of administration, duration of treatment, and method of osteoporosis induction, is an inherent challenge in any meta-analysis of preclinical literature.

What makes this publication notable in the broader landscape is its timing and its method. Interest in flavonoids as nutraceutical interventions for chronic disease has surged, but the field has often been criticized for relying on isolated positive studies that fail to replicate. By applying the systematic review machinery, comprehensive database searches, formal risk-of-bias assessment, and quantitative pooling with confidence intervals, to a natural compound, the Zhejiang team has elevated the conversation from anecdote to evidence synthesis. The open-access publication, released on 6 October 2026 under a Creative Commons license, means that researchers anywhere in the world can scrutinize the data, the inclusion criteria, and the statistical methods, a transparency that is increasingly demanded of preclinical research given the field’s well-documented reproducibility problems.

The road from rodent bone to human prescription is long and littered with compounds that looked spectacular in animal models and failed in clinical trials. Quercetin will need to clear the same hurdles: pharmacokinetic studies establishing achievable human exposure, safety profiling at therapeutic doses, and ultimately randomized controlled trials measuring fracture outcomes, not just surrogate markers. Still, the convergence of evidence from this meta-analysis, antioxidant protection, stem cell fate redirection, and microbiome modulation, paints a coherent mechanistic picture that goes beyond a statistical association. For a compound that costs pennies and sits in the produce aisle, quercetin’s journey from kitchen staple to potential osteoporosis therapy is a story worth watching, and this rigorous synthesis provides the clearest quantitative map yet of where that journey stands today.

Subject of Research: Preclinical efficacy and mechanisms of quercetin in osteoporosis

Article Title: Therapeutic potential of quercetin in osteoporosis: a systematic review and meta-analysis of preclinical studies

Article References: Yan, Z., Liu, L., Su, H., Pan, Y., Chen, W., Zhu, K., Wu, M., Zhuang, R., & Guo, W. (2026). Therapeutic potential of quercetin in osteoporosis: a systematic review and meta-analysis of preclinical studies. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05593-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05593-y

Keywords: quercetin, osteoporosis, meta-analysis, bone density, flavonoids, oxidative stress, bone marrow mesenchymal stem cells, gut microbiota, preclinical studies, bone metabolism, ovariectomy model, antioxidants

The research team, led by Mubarak Muhammad and Botan Salihi of Tishk International University in the Kurdistan Region of Iraq, together with colleagues from Koya University, Universiti Malaysia Sarawak and Universiti Malaya, set out to answer a question that global health authorities have been asking with growing urgency: can traditional medicinal plants be moved from folk knowledge into evidence-based conventional medicine? The World Health Organization has repeatedly noted the worldwide integration of traditional complementary medicine into everyday health care, and plants such as P. odoratum, which is consumed both as a culinary herb and as a remedy across Asia, represent exactly the kind of candidate that deserves rigorous scrutiny rather than anecdotal enthusiasm or dismissive neglect.

Methodologically, the review is a model of caution. The authors searched PubMed, Scopus, Google Scholar and ScienceDirect, applied a PICOS framework to define populations, interventions, comparisons, outcomes and study designs, and then assessed the quality of the included work using two separate instruments: the revised Cochrane Risk-of-Bias tool, known as RoB 2, for randomized trials, and SYRCLE’s risk-of-bias tool, which is tailored to preclinical laboratory animal studies. Because the studies differed so widely in plant extracts, doses, models and endpoints, the heterogeneity was judged too high for a meta-analysis, the statistical technique that pools numerical results across trials. Instead, the team provided descriptive summaries, a decision that reflects an honest reading of the data rather than an attempt to manufacture a single headline number from incomparable experiments.

What emerged from those 34 studies is a spectrum of biological activity that is unusually wide for a single botanical. The most consistently reported effects were antimicrobial and antioxidant. Extracts of the plant showed activity against a range of microorganisms, and the review highlights the abbreviation MRSA, methicillin-resistant Staphylococcus aureus, among the targets examined, a detail that will catch the eye of anyone tracking the antibiotic resistance crisis. Antioxidant activity, meanwhile, ties the herb to one of the central narratives of modern pharmacology: the scavenging of reactive oxygen species that damage DNA, proteins and lipids, and that underlie chronic inflammation, aging and a long list of degenerative diseases.

The molecular signatures reported across the included studies read like a map of the signaling pathways most intensively studied in current drug discovery. Researchers working with P. odoratum extracts have measured effects on nuclear factor kappa B, the master transcription factor of inflammation; on the Nrf2 pathway, the cellular thermostat for antioxidant defense; on the Akt/mTOR axis, a growth and survival circuit central to cancer biology; on mitogen-activated protein kinase signaling; and on inflammatory mediators such as tumor necrosis factor-alpha, interleukin-6, cyclooxygenase-2, inducible nitric oxide synthase and prostaglandin E2. Other studies traced changes in the balance of Bax and Bcl-2, proteins that decide whether a damaged cell lives or enters programmed death, and in matrix metalloproteinase-9 and vascular endothelial growth factor A, both implicated in tumor invasion and blood supply.

Those mechanisms translate into a striking range of reported outcomes. Beyond direct antimicrobial and free-radical scavenging effects, the review catalogued anti-inflammatory actions, anticancer effects, including modulation of cell cycle arrest at the G2/M transition and suppression of Epstein-Barr virus-related markers, and protective activities against a suite of organ-specific disorders. The abbreviation list of the paper hints at the breadth: streptozotocin-induced anti-diabetic models, experiments with human fetal osteoblasts, work on the HT-29 human colon tumor cell line, and even references to amyloid-beta 42, the peptide that aggregates in the brains of Alzheimer’s patients. In other words, laboratories around the world have thrown a remarkable variety of disease models at this one plant, and a meaningful fraction of those experiments have come back positive.

Quality assessment offered the review’s most reassuring finding. According to both the RoB 2 and SYRCLE instruments, the majority of the studies assessed demonstrated a low risk of bias. That matters because the systematic review literature on medicinal plants is littered with poorly controlled experiments, small sample sizes and selective reporting, problems that have rightly made clinicians skeptical of the field. Here, the authors found that a substantial share of the preclinical work met modern standards of rigor, which strengthens the case that the reported effects are genuine biological phenomena rather than artifacts of sloppy methodology. The review was funded by Tishk International University with additional support from Malaysia’s Higher Institution Centre of Excellence program, and the funders played no role in the design, analysis or interpretation of the study.

Yet the review’s headline conclusion is a warning as much as a promise. The entire evidence base is derived predominantly from in vitro experiments and animal studies, with only limited clinical data available. A plant extract that kills bacteria in a petri dish, dampens NF-kappa-B signaling in cultured cells and protects a mouse from chemically induced diabetes has cleared none of the hurdles that matter most to a physician: absorption, distribution, metabolism, toxicity at human doses, drug interactions and, above all, demonstrated benefit in randomized, placebo-controlled human trials. History is full of botanical compounds that dazzled in the laboratory and vanished at the clinic door, and the authors are explicit that well-designed clinical trials and further mechanistic investigations are warranted before any recommendation can be made for integrating P. odoratum into conventional practice.

The translational path forward is nonetheless concrete. The diversity of activities documented in the review suggests that the plant’s secondary metabolites, the chemical compounds it produces for its own defense, interact with multiple pharmacological targets at once, a profile that could yield lead molecules for antibiotic adjuncts, anti-inflammatory agents or antioxidant therapeutics. Standardizing extracts, isolating the active constituents and identifying the precise molecular interactions would be the natural next steps, followed by the preclinical toxicology that separates a promising phytochemical from a drug candidate. The review’s descriptive framework gives researchers a consolidated map of what has already been tested, which plant parts and extraction methods were used, which pathways were probed and where the gaps in coverage lie, potentially saving years of duplicated effort.

For now, the significance of the paper lies less in any single result than in its demonstration that a widely eaten herb has accumulated a serious, quality-controlled body of laboratory evidence. Polygonum odoratum has traveled from market stalls in Hanoi and Bangkok through 34 peer-reviewed studies to a formal systematic review registered in PROSPERO, and it arrives there with its reputation intact but its clinical file nearly empty. Whether the Vietnamese coriander on a dinner plate becomes the source of a future prescription will depend on the clinical trials the authors call for, and on whether the pathways modulated in glass dishes and animal models survive the far harsher test of the human body. The herb, at least, has earned the chance to make that attempt.

Subject of Research: Systematic review of the antimicrobial, antioxidant and other biological activities of the medicinal plant Polygonum odoratum

Article Title: Exploration of Polygonum odoratum as a medicinal plant with promising antimicrobial and antioxidant effects for translational use in conventional medicine: a systematic review

Article References: Muhammad, M., Salihi, B., Star, H., Abdullah, Y. A., Hama-Salim, H., Hama, H. A., Ali, A., Chung, H. H., & Loong, S. K. (2026). Exploration of Polygonum odoratum as a medicinal plant with promising antimicrobial and antioxidant effects for translational use in conventional medicine: a systematic review. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05577-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05577-y

Keywords: Polygonum odoratum, Vietnamese coriander, antimicrobial, antioxidant, systematic review, medicinal plants, anti-inflammatory, anticancer, MRSA, preclinical studies, traditional medicine, drug discovery